| Mark Engibous, CRNA | |
|
338 E Bannock St, Boise, ID 83712-6207 | |
| (208) 336-0895 | |
| Not Available |
| Full Name | Mark Engibous |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 8 Years |
| Location | 338 E Bannock St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083151146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 54877 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Mccall | Mccall, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Boise, P.a. | 2668385287 | 153 |
News Archive
Researchers have created a new model for predicting decompression sickness after deep-sea dives that not only estimates the risk, but how severe the symptoms are likely to be.
A new review article, published on the medRxiv* preprint server, deals with several different aspects such as medical response capability, disaster health management, disaster preparedness, and health infrastructure safety, in China, by which they survived the COVID-19 crisis.
Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
› Verified 7 days ago
| Entity Name | Anesthesia Associates Of Boise, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033147467 PECOS PAC ID: 2668385287 Enrollment ID: O20031110000655 |
News Archive
Researchers have created a new model for predicting decompression sickness after deep-sea dives that not only estimates the risk, but how severe the symptoms are likely to be.
A new review article, published on the medRxiv* preprint server, deals with several different aspects such as medical response capability, disaster health management, disaster preparedness, and health infrastructure safety, in China, by which they survived the COVID-19 crisis.
Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Engibous, CRNA 338 E Bannock St, Boise, ID 83712-6207 Ph: (208) 336-0895 | Mark Engibous, CRNA 338 E Bannock St, Boise, ID 83712-6207 Ph: (208) 336-0895 |
News Archive
Researchers have created a new model for predicting decompression sickness after deep-sea dives that not only estimates the risk, but how severe the symptoms are likely to be.
A new review article, published on the medRxiv* preprint server, deals with several different aspects such as medical response capability, disaster health management, disaster preparedness, and health infrastructure safety, in China, by which they survived the COVID-19 crisis.
Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
› Verified 7 days ago
Mr. Douglas Neurath, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 111 W State St, Boise, ID 83702 Phone: 208-336-0895 | |
Jordan B Wolff, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 111 W State St, Boise, ID 83702 Phone: 208-336-0895 Fax: 208-338-1796 | |
Nathan S Call, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2222 | |
Ashton Mieritz, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2121 | |
Kenneth Clark Stratton Jr., CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2559 | |
Diana San Juan Shimko, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-6416 | |
David Hansen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 338 E Bannock St, Boise, ID 83712 Phone: 208-336-0895 |